The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $9.45 in the prior trading day, Arcutis Biotherapeutics Inc (NASDAQ: ARQT) closed at $9.10, down -3.70%. In other words, the price has decreased by -$3.70 from its previous closing price. On the day, 4.52 million shares were traded. ARQT stock price reached its highest trading level at $9.455 during the session, while it also had its lowest trading level at $8.435.
Ratios:
Our goal is to gain a better understanding of ARQT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.80 and its Current Ratio is at 7.08. In the meantime, Its Debt-to-Equity ratio is 2.32 whereas as Long-Term Debt/Eq ratio is at 2.31.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on January 03, 2024, Upgraded its rating to Buy and sets its target price to $8 from $4 previously.
On October 26, 2023, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $57 to $4.
Goldman Downgraded its Buy to Neutral on October 13, 2023, whereas the target price for the stock was revised from $32 to $6.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 04 ’24 when Heron Patrick J bought 21,052 shares for $9.50 per share. The transaction valued at 199,994 led to the insider holds 8,785,284 shares of the business.
Watanabe Todd Franklin sold 14,903 shares of ARQT for $165,739 on Mar 04 ’24. The insider now owns 874,533 shares after completing the transaction at $11.12 per share. On Mar 04 ’24, another insider, Burnett Patrick, who serves as the insider of the company, sold 4,782 shares for $11.12 each. As a result, the insider received 53,182 and left with 269,300 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 1046236160 and an Enterprise Value of 815056576. Its current Enterprise Value per Revenue stands at 13.674 whereas that against EBITDA is -3.402.
Stock Price History:
The Beta on a monthly basis for ARQT is 1.15, which has changed by -0.31475902 over the last 52 weeks, in comparison to a change of 0.2006725 over the same period for the S&P500. Over the past 52 weeks, ARQT has reached a high of $15.21, while it has fallen to a 52-week low of $1.76. The 50-Day Moving Average of the stock is -7.66%, while the 200-Day Moving Average is calculated to be 39.61%.
Shares Statistics:
The stock has traded on average 4.66M shares per day over the past 3-months and 3309540 shares per day over the last 10 days, according to various share statistics. A total of 114.97M shares are outstanding, with a floating share count of 97.27M. Insiders hold about 15.40% of the company’s shares, while institutions hold 84.39% stake in the company. Shares short for ARQT as of 1711584000 were 19256755 with a Short Ratio of 4.13, compared to 1709164800 on 15781819. Therefore, it implies a Short% of Shares Outstanding of 19256755 and a Short% of Float of 20.200000000000003.
Earnings Estimates
Arcutis Biotherapeutics Inc (ARQT) is currently under the scrutiny of 5 analysts, each contributing to the ongoing evaluation of its stock.On average, analysts expect EPS of -$0.74 for the current quarter, with a high estimate of -$0.65 and a low estimate of -$0.91, while EPS last year was -$1.31. The consensus estimate for the next quarter is -$0.69, with high estimates of -$0.63 and low estimates of -$0.87.
Analysts are recommending an EPS of between -$2.21 and -$3.14 for the fiscal current year, implying an average EPS of -$2.51. EPS for the following year is -$1.46, with 6 analysts recommending between -$1.07 and -$1.95.
Revenue Estimates
5 analysts predict $13.94M in revenue for the current quarter. It ranges from a high estimate of $15.5M to a low estimate of $13M. As of the current estimate, Arcutis Biotherapeutics Inc’s year-ago sales were $2.78M, an estimated increase of 401.30% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $21.64M, an increase of 317.00% less than the figure of $401.30% in the same quarter last year. There is a high estimate of $26.5M for the next quarter, whereas the lowest estimate is $16M.
A total of 6 analysts have provided revenue estimates for ARQT’s current fiscal year. The highest revenue estimate was $122.5M, while the lowest revenue estimate was $75M, resulting in an average revenue estimate of $105.27M. In the same quarter a year ago, actual revenue was $59.61M, up 76.60% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $213.96M in the next fiscal year. The high estimate is $249M and the low estimate is $165M. The average revenue growth estimate for next year is up 103.20% from the average revenue estimate for this year.
